TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03896412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detecton of circulating tumor DNA
Description: 7 blood samples to design a molecular probe
Study: NCT00410982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Day -10 = 32 mg/m\^2 Intravenous Test Dose; Days -8 thru -5 = 105 mg/m\^2 Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Day -8 = 75 mg/m\^2 Intravenous bolus; Day -3 = 75 mg/m\^2 Intravenous bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Day -3 and Day -2 = 60 mg/m\^2 Intravenous.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Infusion of stem cells on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab for Patients with B-Cell Malignancies
Description: 375 mg/m\^2 Intravenous on Days 1 and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: 60 microgram/kg by vein on Days -13 to -11 and Days 0, +1, +2
Study: NCT00221026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxsalen +ECP
Description: ECP + Uvadex given at weeks 1-12 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis
Description: ECP given at weeks 1 through 12.
Study: NCT02395146

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monitoring
Description: intraoperative EBSLN monitoring
Study: NCT03093077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DePuy ATTUNE total knee arthroplasty system
Description: A standard midvastus approach will be used for both alignment technique groups. This is a standard approach for exposing the knee joint for TKA.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DePuy ATTUNE total knee arthroplasty system
Description: A standard midvastus approach will be used for both alignment technique groups. This is a standard approach for exposing the knee joint for TKA.
Study: NCT00209716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: 30 mg/m2, IV (in the vein) on day 1 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 800 mg/m2, CIV (CIV.in the vein) on day 1\~5 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Briplatin
Description: 15 mg/m2, IV (in the vein) on day 1\~4 of each 28 day cycle.
Study: NCT00614965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan at the dose of 110 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin at the dose of 80 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin at the dose of 80 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed at the dose of 500mg/m2 IV every 3 weeks for 6 consecutive cycles
Study: NCT02784249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goniotomy
Description: Procedure: Goniotomy and trabecular excision with a novel ophthalmic knife in combination with planned cataract extraction via Phaco and PCIOL implant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trabecular Micro-Bypass Stent
Description: Procedure: Trabecular Micro-Bypass stent implantation in combination with planned cataract extraction via Phaco and PCIOL implant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Extraction
Description: Cataract extraction via Phaco and PCIOL implant.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract Extraction
Description: Cataract extraction via Phaco and PCIOL implant.
Study: NCT04547283

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: No clinical team recommendation, patients will remain in their natural choice of position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APPS
Description: Clinical team guidance on prone positioning of patients
Study: NCT00866970

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD518
Description: ALD518 80 mg on Day 1, Week 8 and Week 16

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD518
Description: ALD518 160 mg IV on Day 1, Week 8 and Week 16

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD518
Description: ALD518 360 mg IV on Day 1, Week 8, and Week 16

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Infusion of 0.9% Saline without ALD518
Description: Infusion of 0.9% Saline without addition of ALD518
Study: NCT00759005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol and cortisol
Study: NCT02835118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surotomycin
Description: Two oral doses of surotomycin in hard gelatin capsules totaling either 0.5, 1 or 2 g per day, for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surotomycin
Description: Two oral doses of surotomycin in hard gelatin capsules totaling either 0.5, 1 or 2 g per day, for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surotomycin
Description: Two oral doses of surotomycin in hard gelatin capsules totaling either 0.5, 1 or 2 g per day, for 14 days
Study: NCT02014272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: reference drugs
Description: Each subject will receive a single oral dose of 4 x 150 mg rifampicin capsules and 3 x 100 mg isoniazid capsules.
Study: NCT03281044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota capsules
Description: Patients will receive FMT capsules DE containing the fecal microbiota drug substance within a gelatin capsule shell. The drug substance is fecal microbiota from a single donor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The control condition is a placebo FMT capsule. The FMT placebo capsule is identical in appearance to active capsules, but does not contain human feces, the active pharmaceutical ingredient. Placebo capsules will contain an autoclaved solution of glycerol and saline, contained in an identical gelatin capsule as the active product, including the same enteric polymer coating
Study: NCT02835118

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two oral doses of placebo for surotomycin in hard gelatin capsules per day, for 14 days
Study: NCT04554043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280
Description: treatment
Study: NCT00488397

Intervention type: OTHER
Intervention: In-vitro testing
Description: This is an in-vitro study thus only one group in the study and there is no intervention treatment nor procedure involved in this study.
Study: NCT02491762

Intervention type: PROCEDURE
Intervention: respiratory function tests
Description: FVC, FEV1, MVV, FRC, RV, TLC, MIP, MEP

Intervention type: PROCEDURE
Intervention: respiratory function tests
Description: FVC, FEV1, MVV, FRC, RV, TLC, MIP, MEP
Study: NCT04040439

Intervention type: DRUG
Intervention: Dexmedetomidine Hydrochloride
Description: \[Sedation during and after mechanical ventilation in the intensive care setting\] For pediatric patients ages of 6 years and over, dexmedetomidine is usually administrated by continuous intravenous (IV) infusion of at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.0 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition.~For pediatric patients with corrected gestational ages (gestational age + postnatal age) of 45 weeks to under 6 years, dexmedetomidine is usually administrated by continuous IV infusion at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.4 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition. The dosing rate could be decreased according to the patient's condition as appropriate.
Study: NCT01170585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: All patients will be uptitrated from an initial start dose of 5mg to 20mg rosuvastatin. This will be given once a day for 2 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02849028

Intervention type: BEHAVIORAL
Intervention: sleep disorder
Description: The study is to investigate whether exist the relationship between sleep disorder and circadian rhythm of patients with TBI or not.

Intervention type: BEHAVIORAL
Intervention: sleep disorder
Description: The study is to investigate whether exist the relationship between sleep disorder and circadian rhythm of patients with TBI or not.
Study: NCT03563222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smoflipid
Description: The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid, 20%
Description: The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy.
Study: NCT04554043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280
Description: treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280
Description: treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280
Description: treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280
Description: treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280
Description: treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280
Description: treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280
Description: treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280
Description: treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280
Description: treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: blank control
Study: NCT03809390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal seeding
Description: The same as that stated in arm descriptions.
Study: NCT03736967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500
Description: Administered subcutaneous (SC) every 2 weeks (q2w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500
Description: Administered subcutaneous (SC) every 2 weeks (q2w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Administered SC q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Administered SC q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500 + Dupilumab Combo
Description: Administered SC q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC q2w
Study: NCT01030146

Intervention type: DRUG
Group type: OTHER
Intervention: NeilMed® Sinus Rinse™ System with Isotonic Saline
Description: NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
Study: NCT02841696

Intervention type: DEVICE
Intervention: Cardiac echography
Description: The exam is in the left lateral decubitus position. 4 electrodes are applied to the patient's chest for a synchronization with the Electrocardiogram (ECG). The examination is conducted as standard with acquisition loops of records in parasternal long axis parasternal short axis, apical 4-cavities, 2-cavities and aorta 2 cavities.
Study: NCT04554043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: blank control
Study: NCT04500808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan Dose 1
Description: Participants will receive Dose 1 of macitentan tablet in Part 1.
Study: NCT04554043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: blank control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: blank control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: blank control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: blank control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: blank control
Study: NCT04500808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan Dose 2
Description: Participants will receive Dose 2 of macitentan tablet in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan Dose 3
Description: Participants will receive Dose 2 of macitentan tablet in Part 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan Dose 3
Description: Participants will receive Dose 2 of macitentan tablet in Part 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan Dose 3
Description: Participants will receive Dose 2 of macitentan tablet in Part 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo from Day 1 up to Day 13.
Study: NCT00208364

Intervention type: DEVICE
Group type: OTHER
Intervention: Pinnacle Acetabular Cup System
Description: A cementless acetabular cup with metal liner for use in total hip replacement
Study: NCT04320498

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: prp injection
Description: PRP was injected locally in the anal fissure area and glyceryl trinitrate was administered twice daily in the perianal region as in the control group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anrecta
Description: self-administered topical glyceryl trinitrate (anrecta), in the perianal area twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anrecta
Description: self-administered topical glyceryl trinitrate (anrecta), in the perianal area twice a day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sitz bath
Description: participants were told to take a hot water sitz bath once a day

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sitz bath
Description: participants were told to take a hot water sitz bath once a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutrition regulation
Description: The study participants were told to eat a fiber-rich diet and to drink least 2 liters of water daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutrition regulation
Description: The study participants were told to eat a fiber-rich diet and to drink least 2 liters of water daily
Study: NCT01403662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline (100 mg bid) will be administered as an adjunctive agent to conventional Health Canada-approved, or first-line CANMAT bipolar guideline-recommended, agents for bipolar disorder.
Study: NCT00176046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: viscum album pini
Description: s.c. injection of 0,001-20 mg 3 times per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: viscum album pini
Description: s.c. injection 0,001-20 mg 3 times per week
Study: NCT03191799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Initial dosing will be 3 mg/kg/week subcutaneously for 4 weeks; Maintenance dosing will follow at 1.5 mg/kg/week subcutaneously for the remainder of the 2-year treatment period
Study: NCT03387605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: ivabradine or placebo given orally 2 times daily for 72 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo given 2 times daily for 72 hours
Study: NCT04204005

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics
Description: Active composition: 5x109 of Bifidobacterium longum (mix DLBL), 1x 109 Lactobacillus reuteri LRE02 (DSM 23878) and maltodextrin (total 2 grams). The probiotic species employed were granted the Qualified Presumption of Safety (QPS) status by the European Food Safety Authority (EFSA) in 2007. Two envelopes per day and one envelope per day will be recommended for one and two months, respectively.~Placebo composition: maltodextrin (2 grams). Two envelopes per day and one envelope per day will be recommended for one and two months, respectively.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Active composition: 5x109 of Bifidobacterium longum (mix DLBL), 1x 109 Lactobacillus reuteri LRE02 (DSM 23878) and maltodextrin (total 2 grams). The probiotic species employed were granted the Qualified Presumption of Safety (QPS) status by the European Food Safety Authority (EFSA) in 2007. Two envelopes per day and one envelope per day will be recommended for one and two months, respectively.~Placebo composition: maltodextrin (2 grams). Two envelopes per day and one envelope per day will be recommended for one and two months, respectively.
Study: NCT04554043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: blank control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: blank control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: blank control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: blank control
Study: NCT04345003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myoma elastography
Description: The standard pre-therapeutic assessment includes a pelvic US to eliminate the presence of calcification of fibroids. If this absence is confirmed, the elasticity of uterine myoma (by ARFI method) will be measured.~The standard pre-therapeutic MRI performed allows to classify and measure the myoma in order to determine if it is accessible for HIFU treatment. MRI elastography sequence with the Resoundant® system will be performed during this exam.
Study: NCT02669875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serelaxin
Description: Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution (20mM sodium acetate pH5) diluted in 5% v/v glucose solution
Study: NCT01227369

Intervention type: OTHER
Intervention: OPSAT-Q
Description: A linguistically validated Korean version of OPSAT-Q
Study: NCT02755753

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lansoprazole
Description: Oral administration of Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast
Study: NCT01148147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Intracoronary adenosine administration (180 ug for LCA and 120 ug for RCA)
Study: NCT02755753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Oral administration of Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast
Study: NCT01148147

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intracoronary Placebo administration
Study: NCT01986075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted behavior therapy
Description: TES is a computer-assisted therapy program delivered via effective informational and multimedia technologies, includes 32 core interactive, multimedia modules, beginning with basic cognitive behavioral relapse prevention skills (e.g. drug refusal skills) and moving on to improving psychosocial functioning, (e.g. employment status, social relations) and HIV risk reduction.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computer-assisted behavior therapy
Description: TES is a computer-assisted therapy program delivered via effective informational and multimedia technologies, includes 32 core interactive, multimedia modules, beginning with basic cognitive behavioral relapse prevention skills (e.g. drug refusal skills) and moving on to improving psychosocial functioning, (e.g. employment status, social relations) and HIV risk reduction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixed-Amphetamine Salts- Extended Release (MAS-ER)
Description: 80 mg/day of Mixed-Amphetamine Salts- Extended Release (MAS-ER) and computer -assisted CBT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will receive computer -assisted CBT and placebo (instead of active Adderall-XR)
Study: NCT00587626

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inactive InterX 5000
Description: Patients will receive will receive InterX placebo treatment 3 times a week for 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InterX 5000 Treatment
Description: Patients will receive will receive InterX treatment 3 times a week for 4 weeks.
Study: NCT03347890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml or Placebo
Description: Patients will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg) or Placebo by pen injector.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml or Placebo
Description: Patients will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg) or Placebo by pen injector.